PCVX logo

PCVX Vaxcyte, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$58.36
-0.16 (-0.27%)

Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive p…

Market Cap: $9.24Bvaxcyte.com

Price

No data yet.

Social Signal Score

58
5d
—
30d
70
1 mentions
—
60d
52
21 mentions
—
90d
52
31 mentions
—
news: 15 · rss: 12 · marketaux: 4

Analyst Ratings

11 analysts
Buyconsensus
Strong Buy 0Buy 11Hold 0Sell 0Strong Sell 0
Avg price target$122.33+109.6%
Low $120Median $122High $125
Current Consensus

Revenue

$0.00
$0.00
Mar 2019Sep 2026

Analyst Estimates

FY2025
$-5.44
$-6.21–$-4.89
5 analysts
FY2026
$-7.86
$-8.58–$-7.44
6 analysts
FY2027
$-6.68
$-8.17–$-4.81
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Grant E. Pickering
Sector
Healthcare
Industry
Biotechnology
Employees
507
Beta
1.29
Country
US
Piotroski score
0 / 9 (Weak)
Altman Z-score
8.80
vaxcyte.com